Hepatitis B vaccine market seen reaching $17.2B by 2035

Market Research Future projects the global hepatitis B vaccine market will rise from $9.05 billion in 2025 to $17.20 billion by 2035, fueled by birth-dose mandates, Gavi co-financing and newer delivery platforms. The forecast points to stronger demand in pediatric and adult segments, with Asia-Pacific and North America driving much of the growth.

Why it matters: - The hepatitis B vaccine market is moving from a pediatric public-health category into a broader, multi-channel market with durable demand from infants, adults and catch-up vaccination. - The projected rise to $17.20 billion by 2035 implies steady procurement growth for governments, manufacturers and global health buyers. - The market’s growth is tied to birth-dose coverage, elimination goals and delivery innovation that can expand access in lower-income and harder-to-reach settings.

What happened: - Market Research Future estimated the global hepatitis B vaccine market at $9.05 billion in 2025. - The firm projects the market will reach $9.65 billion in 2026 and $17.20 billion by 2035. - The forecast implies a 6.65% compound annual growth rate for 2026-2035. - The report says government birth-dose mandates, Gavi co-financing and delivery technology shifts are the main growth drivers.

The details: - National immunization schedules increasingly require a hepatitis B dose within 24 hours of birth. - The WHO South-East Asia Region reported birth-dose coverage rising above 60% in 2024. - India’s Universal Immunization Programme provides free hepatitis B vaccination as part of a 12-disease schedule. - India’s under-5 mortality rate fell from 45 to 32 per 1,000 live births between 2014 and 2020. - China’s universal birth-dose program has exceeded 95% timely coverage since the 1990s. - France and Italy run universal mandatory infant vaccination. - The CDC’s 2022 recommendation extended hepatitis B vaccination to all adults ages 19-59 in the U.S. - Gavi has distributed nearly $1.6 billion in vaccination support across hepatitis-inclusive initiatives in recent cycles. - Gavi’s co-financing model requires low-income countries to share costs over time, which steadies demand. - UNICEF and PAHO revolving funds push per-dose prices down to a few cents in low-income tiers. - UNICEF Supply Division weighted average hepatitis B prices have remained under $0.30 per dose in recent tenders. - Recombinant single-antigen vaccines held about 58% of revenue in 2025. - Combination vaccines are the fastest-growing vaccine type, with a projected 7.8% CAGR from 2026 to 2035. - Pediatric demand was about $5.62 billion in 2025, or roughly 62% of the market. - Adult demand is the fastest-growing age segment, projected at 6.9% CAGR. - Government organizations accounted for about 54% of distribution share in 2025. - Hospitals represented $2.45 billion in 2025. - Retail pharmacies, online portals and NGO channels are gaining share as adult and outreach demand expands. - North America held about 33% of the market in 2025. - The U.S. generated about 84% of North American hepatitis B vaccine revenue. - Europe was the second-largest region at $2.30 billion in 2025. - Asia-Pacific is the fastest-growing region, projected at 7.4% CAGR. - China is the largest Asia-Pacific market and is growing at 6.9% CAGR. - India is projected to grow at 8.3% CAGR. - The Middle East and Africa region is projected to grow at 8.1% CAGR. - South America reached $0.78 billion in 2025, with Brazil accounting for about 62% of regional revenue. - The market is moderately concentrated, with the top five suppliers holding roughly 62% to 68% of global revenue. - GlaxoSmithKline, Merck, Serum Institute of India, Sanofi, Dynavax Technologies and Bharat Biotech are among the leading companies named in the report. - In May 2024, Serum Institute of India took a 20% stake in IntegriMedical to scale needle-free injection system technology. - In June 2024, Sanofi secured additional WHO prequalification volumes for its hexavalent combination vaccine. - In March 2024, Dynavax reported expanded Heplisav-B uptake in U.S. retail pharmacy channels. - In September 2023, Bharat Biotech expanded Revac-B production capacity for pentavalent demand across African tenders.

Between the lines: - The market’s value growth is being pulled toward adult, premium and combination products, while monovalent birth-dose supply faces heavy price pressure in pooled procurement markets. - Lower-priced procurement through UNICEF and PAHO helps expand access, but it also caps manufacturer margins. - Needle-free injectors, prefilled syringes and microarray patches could widen administration settings beyond clinics and hospitals. - Digital immunization registries and defaulter tracking may become a new layer of value for manufacturers and governments by improving coverage and forecasting. - Africa’s push for local vaccine production could reshape tender dynamics and reduce import dependence over time.

What’s next: - WHO’s 2030 hepatitis elimination goals will keep pressure on countries to sustain high birth-dose coverage. - Digital registry adoption is expected to expand through the early 2030s, improving tracking and procurement planning. - Needle-free delivery platforms and microarray patches are likely to gain more visibility as scale lowers device costs. - Continued expansion of local manufacturing in Africa could alter supply routes and pricing in emerging markets. - The report expects the market to keep consolidating around companies that can combine manufacturing, data and delivery innovation.